Clinical Trial

The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of cytokine-induced killer cell (CIK) plus S-1 and Bevacizumab vs S-1 and Bevacizumab as Maintenance Treatment for patients with advanced colorectal cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2015-06-30.
Status change: Not Yet Recruiting → Active, Not Recruiting 2016-02-23
Trial Details
NCT Number NCT02487992
Lead Sponsor The First People's Hospital of Changzhou
Conditions Colorectal Neoplasms
Enrollment 1,200 participants
Start Date 2015-07
Primary Completion 2043-07 (estimated)
Study Completion 2045-07 (estimated)
Updated on ClinicalTrials.gov 2016-02-24